SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche1/2/2020 2:36:36 PM
   of 435
 
Obvious that such molecules exist, so this is filed under "duh!"......

Sci Rep. 2019 Dec 30;9(1):20335. doi: 10.1038/s41598-019-56785-1.

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than ?9-tetrahydrocannabinol: ?9-Tetrahydrocannabiphorol.

Citti C1,2,3, Linciano P3, Russo F3, Luongo L4, Iannotta M4, Maione S4, Laganà A2,5, Capriotti AL5, Forni F3, Vandelli MA3, Gigli G2, Cannazza G6,7.

1
Mediteknology spin-off company of the National Council of Research (CNR), Via Arnesano, 73100, Lecce, Italy.
2
Institute of Nanotechnology of the National Council of Research (CNR NANOTEC), Via Monteroni, 73100, Lecce, Italy.
3
Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125, Modena, Italy.
4
Department of Experimental Medicine, Division of Pharmacology, Università della Campania "L. Vanvitelli", Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.
5
Department of Chemistry, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
6
Institute of Nanotechnology of the National Council of Research (CNR NANOTEC), Via Monteroni, 73100, Lecce, Italy. giuseppe.cannazza@unimore.it.
7
Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125, Modena, Italy. giuseppe.cannazza@unimore.it.

(-)-Trans-?9-tetrahydrocannabinol (?9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of ?9-THC with a longer side chain have shown cannabimimetic properties far higher than ?9-THC itself. In the attempt to define the phytocannabinoids profile that characterizes a medicinal cannabis variety, a new phytocannabinoid with the same structure of ?9-THC but with a seven-term alkyl side chain was identified. The natural compound was isolated and fully characterized and its stereochemical configuration was assigned by match with the same compound obtained by a stereoselective synthesis. This new phytocannabinoid has been called (-)-trans-?9-tetrahydrocannabiphorol (?9-THCP). Along with ?9-THCP, the corresponding cannabidiol (CBD) homolog with seven-term side alkyl chain (CBDP) was also isolated and unambiguously identified by match with its synthetic counterpart. The binding activity of ?9-THCP against human CB1 receptor in vitro (Ki?=?1.2?nM) resulted similar to that of CP55940 (Ki?=?0.9?nM), a potent full CB1 agonist. In the cannabinoid tetrad pharmacological test, ?9-THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity. The presence of this new phytocannabinoid could account for the pharmacological properties of some cannabis varieties difficult to explain by the presence of the sole ?9-THC.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext